We would love to hear your thoughts on the episodes!Dr. Thomas Nero speaks with Dr Peter Toth about the dramatic change occuring in diabtetes management and its effect on cardiovascular disease.  Starting with the biochemestry of diabetes and its effects at the cellular level, the discussion goes on to speak about the role SGLT2 inhibitors and GLP1 receptor agonists play in DM management as well as the future of diabetes care.  (If you want to skip the excelllent, but quite deep dive into biochemistry, jump to 11:22 - but honestly Dr. Toth's description is breathtaking)

We would love to hear your thoughts on the episodes!Dr. Thomas Nero speaks with Dr. Peter Toth about the complex biology of lipids and atherosclerosis.  In this episode Dr Toth dives into LDL goals, therapies for attenuating non-LDL risk, vascular biology and the where are research studies lead us in choosing therapies.

We would love to hear your thoughts on the episodes!Dr Paul Ridker discusses his paper on residual inflammatory risk that was recently published in the Lancet with Dr. Thomas Nero.  He discusses the pathology of inflammation as part of atherosclerosis, utilization of hs-CRP in clinical trials and in daily practice as well as current therapeutic options and ongoing investigations.

Dr. Christopher Cannon, a renowned cardiologist and professor at Harvard, dives into the fascinating world of Pragmatic Clinical Trials alongside Dr. Thomas Nero. They discuss the EVOLVE-MI trial, highlighting the early use of Evolocumab post-myocardial infarction. The conversation unveils the importance of real-world data, patient-centric trial design, and customizing LDL cholesterol targets to enhance cardiovascular care. Cannon emphasizes the need for streamlined participation to improve patient outcomes and the future potential of evolving research strategies.

We would love to hear your thoughts on the episodes!Dr Sharonne Hayes of the May Clinic discusses SCAD with Dr. Thomas Nero.  Initially focusing on the new treatment paradigms, their wide ranging discussion covers etiology, pathophysiology and potential future therapeutic options.  Tis is the first of a two part podcast.

We would love to hear your thoughts on the episodes!Dr Sharoanne Hayes and Dr. Thomas Nero continue their discussion of SCAD focusing on genetics, trial design and the role of online registries as well as the holistic treatment of the SCAD patient.  This is part two of two.

We would love to hear your thoughts on the episodes!Dr. Nero discusses evaluation of  coronary artery disease and coronary inflammaiton with Dr. Cheerag Shirodaria from the University of Oxford.  Dr. Shirodaria along with Prof. Charalambos Antonidies at Caristo Diagnostics have developed a ground breaking technology that allows us to evaluate not just the severity of a coronary artery lesion, but also how inflamed it is and how likely it is to cause fatal and non-fatal myocardial infarction.  In addition, since it is a biologically active "marker" the Fat Attenuation Index (FAI) can also be used a a way to evaluate success of medical intervention.  Using computer post processing from standard 64 or 128 slice CT coronary angiography, they have been able to evaluate not just the vulnerable patient but also (possibly) the vulnerable plaque.

We would love to hear your thoughts on the episodes!Prof. Christine Coughlin of Wake Forest School of Law speaks with Dr. Thomas Nero on the FDA approval process, emergency use authorization, Right to Try Legislation and the implications for clinical research, diversity and health care equity.  Prof. Coughlin holds positions in the College of Medicine as well as the Law school and in the Center for Bioethics.  She has published extensively on the FDA approval process.

We would love to hear your thoughts on the episodes!Although exercise usually provides a cardiovascular benefit, there is some data that points to an increase in event rates in extreme endurance athletes.  In this episode, Dr. Thomas Nero and Dr. Paul Thompson discuss the surprising findings regarding coronary calcium, cardiac troponins and atrial fibrillation in the endurance athlete and some thoughts about ideas to pursue in future research.

In this discussion, Dr. Paul Thompson, a renowned expert in lipid metabolism and sports cardiology, shares insights on Statin Associated Muscle Symptoms (SAMS). He delves into the controversial findings of the STOMP and SAMSON trials, emphasizing the complex relationship between statins and muscle issues. The conversation also explores alternative treatments for those intolerant to statins and the impacts of these medications on athletic performance, shedding light on the intricacies of managing hyperlipidemia in patients.